- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 471/16 - Peri-condensed systems
Patent holdings for IPC class C07D 471/16
Total number of patents in this class: 448
10-year publication summary
|
25
|
22
|
32
|
41
|
30
|
31
|
34
|
42
|
34
|
10
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Intra-Cellular Therapies, Inc. | 430 |
98 |
| Merck Patent GmbH | 5716 |
29 |
| Genentech, Inc. | 4052 |
9 |
| Merck Sharp & Dohme LLC | 3702 |
8 |
| Glaxosmithkline Intellectual Property Development Limited | 769 |
7 |
| Glaxo Group Limited | 4288 |
6 |
| Merck Sharp & Dohme Corp. | 2185 |
6 |
| Universal Display Corporation | 2023 |
6 |
| UTi Limited Partnership | 452 |
6 |
| Bristol-myers Squibb Company | 4814 |
5 |
| Samsung Display Co., Ltd. | 37630 |
5 |
| Abbvie Inc. | 1841 |
5 |
| FUJIFILM Corporation | 30206 |
4 |
| Takeda Pharmaceutical Company Limited | 2720 |
4 |
| University of Florida Research Foundation, Inc. | 4133 |
4 |
| Actelion Pharmaceuticals Ltd | 507 |
4 |
| Teva Pharmaceuticals International GmbH | 322 |
4 |
| Shanghaitech University | 371 |
4 |
| Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences | 106 |
4 |
| BeOne Medicines I GmbH | 321 |
4 |
| Other owners | 226 |